孟鲁司特辅助治疗对肺部感染患者临床疗效、炎性因子及免疫功能的影响

Effect of Montelukast Adjuvant Therapy on Clinical Efficacy,Inflammatory Factors and Immune Function in Patients with Pulmonary Infection

目的观察孟鲁司特辅助治疗对肺部感染患者临床疗效、炎性因子及免疫功能的影响。方法选取2020年6月-2022年1月我院收治的62例肺部感染患者为研究对象,采用随机数字表法分为对照组(n=31)和观察组(n=31),对照组采用常规抗感染、解痉平喘治疗,观察组在对照组基础上,增加孟鲁司特辅助治疗。比较两组临床疗效、肺部感染病灶吸收时间、住院时间、炎性因子水平[C反应蛋白(CRP)、血清淀粉样蛋白A(SAA)、白细胞(WBC)、嗜酸性粒细胞(EOS)]、免疫功能指标(免疫球蛋白IgA、T淋巴细胞亚群CD3^(+)、CD4^(+))及不良反应发生率。结果观察组治疗总有效率为93.55%,高于对照组的80.65%(P<0.05);观察组肺部感染病灶吸收时间、住院时间均短于对照组(P<0.05);两组治疗后CRP、SAA、WBC、EOS均低于治疗前,且观察组低于对照组(P<0.05);观察组治疗后IgA、CD3^(+)、CD4^(+)均高于治疗前,且观察组高于对照组(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论孟鲁司特辅助治疗肺部感染可提高临床疗效,有效抑制炎症因子,提升免疫功能,促进病灶吸收,缩短住院时间,且不良反应少,具有良好的临床应用价值。

Objective To observe the effect of montelukast adjuvant therapy on clinical efficacy,inflammatory factors and immune function in patients with pulmonary infection.Methods A total of 62 patients with pulmonary infection admitted to our hospital from June 2020 to January 2022 were selected as the research objects.They were divided into control group(n=31)and observation group(n=31)by random number table method.The control group was treated with conventional anti-infection,spasmolysis and asthma treatment,and the observation group was treated with montelukast adjuvant therapy on the basis of the control group.The clinical efficacy,absorption time of pulmonary infection lesions,hospitalization time,levels of inflammatory factors[C-reactive protein(CRP),serum amyloid A(SAA),white blood cell(WBC),eosinophil(EOS)],immune function indexes(immunoglobulin IgA,T lymphocyte subsets CD3^(+),CD4^(+))and incidence of adverse reactions were compared between the two groups.Results The total effective rate of treatment in the observation group was 93.55%,which was higher than 80.65%in the control group(P<0.05).The absorption time and hospitalization time of pulmonary infection lesions in the observation group were shorter than those in the control group(P<0.05).After treatment,CRP,SAA,WBC and EOS in the two groups were lower than those before treatment,and those in the observation group were lower than those in the control group(P<0.05).After treatment,IgA,CD3^(+)and CD4^(+)in the observation group were higher than those before treatment,and those in the observation group were higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Montelukast adjuvant treatment of pulmonary infection can improve clinical efficacy,effectively inhibit inflammatory factors,improve immune function,promote lesion absorption,shorten hospital stay,and have fewer adverse reactions.It has good clinical application value.